Loading...

Allena Pharmaceuticals

DB:0PJ
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
0PJ
DB
$137M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The last earnings update was 48 days ago. More info.


Add to Portfolio Compare Print
  • Allena Pharmaceuticals has significant price volatility in the past 3 months.
0PJ Share Price and Events
7 Day Returns
1.1%
DB:0PJ
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
-49.4%
DB:0PJ
-7.4%
DE Biotechs
-5.6%
DE Market
0PJ Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Allena Pharmaceuticals (0PJ) 1.1% -6.2% -18.8% -49.4% - -
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • 0PJ underperformed the Biotechs industry which returned -7.4% over the past year.
  • 0PJ underperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Allena Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Allena Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €5.808.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Allena Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Allena Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:0PJ PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.72
NasdaqGS:ALNA Share Price ** NasdaqGS (2019-04-24) in USD $6.59
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Allena Pharmaceuticals.

DB:0PJ PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ALNA Share Price ÷ EPS (both in USD)

= 6.59 ÷ -1.72

-3.83x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Allena Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Allena Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Allena Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:0PJ PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.83x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
-4.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Allena Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Allena Pharmaceuticals's assets?
Raw Data
DB:0PJ PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $2.38
NasdaqGS:ALNA Share Price * NasdaqGS (2019-04-24) in USD $6.59
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:0PJ PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ALNA Share Price ÷ Book Value per Share (both in USD)

= 6.59 ÷ 2.38

2.77x

* Primary Listing of Allena Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Allena Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Allena Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Allena Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Allena Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-4.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Allena Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Allena Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Allena Pharmaceuticals's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Allena Pharmaceuticals's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:0PJ Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:0PJ Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts -4.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:0PJ Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:0PJ Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 315 -20 -30 4
2022-12-31 22 -44 -52 4
2021-12-31 7 -11 -58 1
2020-12-31 0 -51 -49 8
2019-12-31 0 -35 -42 8
DB:0PJ Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -32 -36
2018-09-30 -30 -33
2018-06-30 -25 -28
2018-03-31 -22 -24
2017-12-31 -21 -22
2017-09-30 -20 -21
2017-06-30 -24 -23
2017-03-31 -24 -24
2016-12-31 -23 -25

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Allena Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Allena Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:0PJ Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Allena Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0PJ Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.58 -0.58 -0.58 1.00
2022-12-31 0.62 6.54 -2.00 5.00
2021-12-31 -2.03 -1.00 -2.85 6.00
2020-12-31 -1.89 -1.26 -2.78 8.00
2019-12-31 -1.87 -1.59 -2.24 8.00
DB:0PJ Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.72
2018-09-30 -1.72
2018-06-30 -1.96
2018-03-31 -2.55
2017-12-31 -4.80
2017-09-30 -15.84
2017-06-30 -16.93
2017-03-31 -18.03
2016-12-31 -18.35

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Allena Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Allena Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Allena Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Allena Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Allena Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Allena Pharmaceuticals does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Allena Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Allena Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Allena Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Allena Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0PJ Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -35.65 9.22 26.38
2018-09-30 -32.72 8.52 23.87
2018-06-30 -27.90 7.54 19.50
2018-03-31 -23.90 6.28 17.10
2017-12-31 -21.71 5.43 15.52
2017-09-30 -21.26 4.81 15.57
2017-06-30 -22.73 4.23 17.89
2017-03-31 -24.17 4.25 19.44
2016-12-31 -24.58 4.08 20.10
2015-12-31 -14.28 2.37 11.54

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Allena Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Allena Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Allena Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Allena Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Allena Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Allena Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Allena Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Allena Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Allena Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Allena Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 6.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Allena Pharmaceuticals Company Filings, last reported 3 months ago.

DB:0PJ Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 49.46 9.98 61.64
2018-09-30 58.45 9.98 70.56
2018-06-30 67.35 9.98 78.85
2018-03-31 75.41 8.41 86.38
2017-12-31 82.87 9.39 94.49
2017-09-30 21.78 9.69 33.87
2017-06-30 26.35 9.64 37.96
2017-03-31 36.45 9.59 48.76
2016-12-31 36.45 9.59 48.76
2015-12-31 60.69 6.19 69.01
  • Allena Pharmaceuticals's level of debt (20.2%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Allena Pharmaceuticals's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Allena Pharmaceuticals has sufficient cash runway for 1.9 years based on current free cash flow.
  • Allena Pharmaceuticals has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 20.1% each year.
X
Financial health checks
We assess Allena Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Allena Pharmaceuticals has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Allena Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Allena Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Allena Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Allena Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Allena Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:0PJ Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:0PJ Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Allena Pharmaceuticals has not reported any payouts.
  • Unable to verify if Allena Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Allena Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Allena Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Allena Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Allena Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Allena Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Allena Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Allena Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Lou Brenner
COMPENSATION $665,034
AGE 48
TENURE AS CEO 0.2 years
CEO Bio

Dr. Louis Brenner, also known as Lou, M.D., M.B.A., served as the Chief Operating Officer of Allena Pharmaceuticals, Inc. since April 2015 until January 2019 and has been its President since February 2017. Dr. Brenner serves as Chief Executive Officer at Allena Pharmaceuticals, Inc since January 2019. Dr. Brenner served as the Chief Medical Officer and Senior Vice President of Idera Pharmaceuticals, Inc. from January 9, 2014 to April 3, 2015. Dr. Brenner served as the Chief Medical Officer and Senior Vice President of Radius Health, Inc. from November 1, 2011 to January 2, 2014 and November 2011 to January 2, 2014. Dr. Brenner served as Senior Vice President of AMAG Pharmaceuticals, Inc. (formerly, Advanced Magnetics Inc.) from September 11, 2006 to December 2010 and served as its Chief Medical Officer. He was responsible for the success of the Advanced Magnetics's ferumoxytol program, including all aspects of the submission of the New Drug Application for ferumoxytol as an intravenous iron replacement therapeutic for the treatment of anemia in dialysis-dependent (DD) and non-dialysis dependent (NDD) chronic kidney disease patients (CKD) along with the planning and execution of subsequent indications for ferumoxytol. He is also responsible for building the Medical Affairs group at Advanced Magnetics. From June 2002 to September 2006, Dr. Brenner served in progressively senior roles at Genzyme Corporation, a biotechnology company. He served as Senior Director of Business Development for the Renal and Transplantation Units of Genzyme Corporation. He has more than a decade of industry leadership experience, including pharmaceutical development strategy, regulatory affairs, business development and marketing. His drug development successes include managing the late-stage development and regulatory submission for Feraheme® (ferumoxytol) injection in patients with chronic kidney disease (CKD) at AMAG Pharma; leading the conduct of the global Phase 3 program of a novel candidate for the treatment of osteoporosis at Radius Health; and directing global commercial planning for Renvela® (sevelamer carbonate) in patients with end stage renal disease at Genzyme. He serves as the Chairman of the Board of the National Kidney Foundation serving New England. He has been Director of Goldfinch Biopharma Inc. since February 9, 2017. He served as a Director of PLC Medical Systems, Inc. He served as Director of PLC Systems Inc. from June 2009 to June 15, 2010. He completed his residency in internal medicine at Brigham and Women’s Hospital (BWH) and his fellowship in nephrology at BWH and Massachusetts General Hospital. He is Board Certified in Nephrology and Internal Medicine and cares for patients with kidney disease at Brigham and Women's Hospital in Boston. He has published on a variety of Nephrology topics in leading scientific journals. Dr. Brenner holds a clinical appointment at BWH. Dr. Brenner holds a B.S. in Biology from Yale University, an M.D. from Duke University and an M.B.A. from the Harvard Business School.

CEO Compensation
  • Lou's compensation has increased whilst company is loss making.
  • Lou's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Allena Pharmaceuticals management team in years:

2.8
Average Tenure
55.5
Average Age
  • The tenure for the Allena Pharmaceuticals management team is about average.
Management Team

Alex Margolin

TITLE
Co-Founder & Chairman of the Board
COMPENSATION
$670K
AGE
65
TENURE
8.3 yrs

Lou Brenner

TITLE
CEO & President
COMPENSATION
$665K
AGE
48
TENURE
0.2 yrs

Ed Wholihan

TITLE
CFO and VP of Finance & Administration
COMPENSATION
$424K
AGE
58
TENURE
2.8 yrs

Bob Gallotto

TITLE
Co-Founder & Strategic Adviser
AGE
53
TENURE
4 yrs

Hugh Wight

TITLE
Senior Vice President of Technical Operations

Anna Kausz

TITLE
Chief Medical Officer
TENURE
0.1 yrs
Board of Directors Tenure

Average tenure and age of the Allena Pharmaceuticals board of directors in years:

2.8
Average Tenure
54
Average Age
  • The average tenure for the Allena Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Bob Tepper

TITLE
Director
COMPENSATION
$158K
AGE
62
TENURE
7.6 yrs

Alex Margolin

TITLE
Co-Founder & Chairman of the Board
COMPENSATION
$670K
AGE
65
TENURE
0.3 yrs

Gino Santini

TITLE
Lead Director
COMPENSATION
$118K
AGE
61
TENURE
0.2 yrs

Andrew A. Hack

TITLE
Director
AGE
44
TENURE
0.8 yrs

Jamie Topper

TITLE
Director
COMPENSATION
$159K
AGE
56
TENURE
7.6 yrs

Axel Bolte

TITLE
Director
COMPENSATION
$158K
AGE
46
TENURE
4.5 yrs

Robert Alexander

TITLE
Director
COMPENSATION
$118K
AGE
48
TENURE
2.8 yrs

Alex Vinogradov

TITLE
Board Observer
AGE
45

Allene Diaz

TITLE
Director
AGE
54
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Allena Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Allena Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is headquartered in Newton, Massachusetts.

Details
Name: Allena Pharmaceuticals, Inc.
0PJ
Exchange: DB
Founded: 2011
$122,562,237
20,815,014
Website: http://www.allenapharma.com
Address: Allena Pharmaceuticals, Inc.
One Newton Executive Park,
Suite 202,
Newton,
Massachusetts, 02462,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ALNA Common Shares Nasdaq Global Select US USD 02. Nov 2017
DB 0PJ Common Shares Deutsche Boerse AG DE EUR 02. Nov 2017
Number of employees
Current staff
Staff numbers
49
Allena Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 23:37
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/04/18
Last earnings filing: 2019/03/07
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.